Company Overview and News

 
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.

 
NZ shares fall as Pushpay revenue slips

2018-04-11 nzherald.co.nz
New Zealand shares fell, led by Pushpay Holdings after the mobile app payments developer posted its first dip in quarterly revenue, while blue-chip stocks a2 Milk Co, Fletcher Building and Fisher & Paykel Healthcare declined. Infratil gained on upbeat earnings guidance.

 
Shares rise on optimism US and China will avoid trade war

2018-04-09 nzherald.co.nz
New Zealand shares rose as the local bourse joined a region-wide rally on optimism the US and China will manage to avoid a trade war that could slow global growth. Sky Network Television, Fisher & Paykel Healthcare and Spark NZ led broad-based gains. Orion Health jumped 11 per cent.

 
NZ shares up, Sky TV bounces with Comvita

2018-04-06 nzherald.co.nz
New Zealand shares gained, led by Sky Network Television bouncing back and Orion Health surging 20 per cent after it confirmed it's considering sale options.

 
NZ shares drop; Fletcher closes at 9-year low

2018-04-05 nzherald.co.nz
New Zealand shares fell, led by Sky Network Television, Genesis Energy and Fletcher Building while Kathmandu Holdings and Synlait Milk gained.

 
NZ shares drop; A2, Fletcher fall

2018-03-29 nzherald.co.nz
New Zealand shares fell on the last day of the quarter, led lower by A2 Milk Co on continued selling from increased competition and further weakening from Fletcher Building.

 
MARKET CLOSE: A2 plunges on Nestle competition, Sky TV down 8% on rugby rights

2018-03-28 nbr.co.nz
(BusinessDesk) - New Zealand shares dropped 1.4 percent with A2 Milk Co and Synlait Milk sold off over competition from Nestle in China, while Sky Network Television fell on news it likely won't win the broadcasting rights for the 2019 Rugby World Cup.

 
A2 plunges on Nestle competition, Sky TV down 8% on rugby rights

2018-03-28 nzherald.co.nz
New Zealand shares dropped 1.4 per cent with A2 Milk Co and Synlait Milk sold off over competition from Nestle in China, while Sky Network Television fell on news it likely won't win the broadcasting rights for the 2019 Rugby World Cup.

 
Australia, NZ shares fall following Wall Steet slump

2018-03-28 themalaymailonline
An investor reacts as he looks through a window at boards displaying stock prices at the Australian Securities Exchange (ASX) in Sydney, November 9, 2016. — Reuters picSYDNEY, March 28 — Australian shares slipped in thin trade this morning, as a sharp fall on Wall Street reduced risk appetite and pushed investors to the sidelines.

 
MARKET CLOSE: NZ shares gain, risk-on for Synlait and A2 as Sky TV rises

2018-03-27 nbr.co.nz
New Zealand shares rose, led by Synlait Milk and a2 Milk Co, with Sky Network Television rebounding from yesterday's selling.

 
NZ shares gain; Synlait, A2 and Sky TV rise

2018-03-27 nzherald.co.nz
New Zealand shares rose, led by Synlait Milk and a2 Milk Co, with Sky Network Television rebounding from yesterday's selling.

 
Shares keep falling amid global sell-off

2018-03-26 nzherald.co.nz
New Zealand's S&P/NZX 50 Index fell about 1 per cent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.

 
MARKET CLOSE: NZ shares join global sell-off

2018-03-26 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index fell about 1 percent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.

 
Global appetite for NZ yield stocks on pause, Harbour Asset's Bascand says

2018-03-25 nbr.co.nz
Appetite among global fund managers for high-yielding New Zealand stocks has gone on pause for the last three to six months after two to three years of consistent monthly demand, the managing director of Harbour Asset Management, Andrew Bascand, says.

 
MARKET CLOSE: NZ shares drop 1% on global selloff, US stocks wobble as Trump backs down on spending bill

2018-03-23 nbr.co.nz
New Zealand's NZX 50 Index dropped nearly 1 percent on global trade news in Friday trading., with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 83080U201